{"acquisitions":[],"changes":[],"country":"FR","description":"Inventiva Pharma is a French clinical-stage biopharma focused on lanifibranor, an oral pan-PPAR agonist for metabolic dysfunction-associated steatohepatitis. It targets MASH patients with advanced fibrosis lacking oral options. The Phase 3 NATiV3 trial of 1,000+ patients is expected to read out in H2 2026.","domain":"inventivapharma.com","employees":null,"founded":2012,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":47.352805,"lng":4.998594,"location":"Daix, France","multiples":[],"name":"Inventiva Pharma","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":160920000,"connectionsAmong":[],"currency":"EUR","date":"2025-11-15","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"inventivapharma-com-2025-11-15-public-offering","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"seed","url":null}],"slug":"inventivapharma-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"inventivapharma.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://inventivapharma.com"},{"fact":"description","publisher":"inventivapharma.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://inventivapharma.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Apache HTTP Server","Modernizr","Yoast SEO 27.5","Google Analytics","Google Tag Manager","jQuery Migrate 3.4.1","particles.js","Polylang","DoubleClick Floodlight","CookieYes 3.4.2","OneSignal","OWL Carousel"],"totalRaisedUsd":216000000,"traction":[],"updatedAt":"2026-05-02","valuations":[]}